Antares Pharma (ATRS) Announces Safety Data from QST-15-005 Study
Tweet Send to a Friend
Antares Pharma, Inc. (Nasdaq: ATRS) announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot Testosterone ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE